June 30, 2021, Shanghai, China. ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. (hereinafter referred to as "ImmuneOnco") announced that the first-in-Class drug candidate, Bi-specific recombinant fusion protein targeting human CD47and HER2 named IMM2902 received clinical trial approval from the National Medical Products Administration (NMPA).

On March 05, 2021, ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. (hereinafter refer to as ImmuneOnco) announced receiving ‘Hi-Tech Enterprise Certificate’. This certificate is jointly issued by Shanghai Municipal Science and Technology Commission, Shanghai Municipal Finance Bureau and Shanghai Taxation Bureau of State Administration of Taxation.

On January 20, 2021, ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. announced that the first Fc fusion protein drug targeting human CD47 (Project No.: IMM01) in China, expanding new indications (AML and MDS) and obtaining NMPA clinical trial research license.

On January 9, 2021, ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. announced that the company's self-developed bispecific antibody drug (Project No.: IMM0306) targeting both CD47 and CD20 has obtained the US FDA clinical trial research license. It was only 30 days before the application for IND was submitted to FDA that the company obtained the clinical trial research license, which indicated that the company team had made excellent preparation for CMC and clinical research protocol, and laid a good foundation for many projects to apply for IND in the United States in the future.